Isaac Martin

Staff Physician, Division of Paediatric Respiratory Medicine

Project Investigator, Translational Medicine

Dr. Isaac Martin is a Paediatric Respirologist with a background shaped by experiences in the United Kingdom and Canada. He completed medical school at the University of London, followed by specialty training and paediatrics and doctoral research in cystic fibrosis lung infection at Imperial College London. He joined The Hospital for Sick Children (SickKids) as a Staff Respirologist in September 2024.

Research

Dr. Isaac Martin developed his research interest within the sphere of the evolving cystic fibrosis (CF) care model. Within CF and other chronic lung diseases, opportunistic respiratory infections are a major cause of mortality and morbidity. There is a pressing clinical need to focus on optimizing the detection and treatment of lung infection, to develop novel antimicrobial strategies and to promote development of these strategies into clinical practice with well-designed and robust clinical trials. His research encompasses both clinical and laboratory-based methods and aims to address these three needs.

Education and experience

• 2023–2024: Paediatric Respirologist, London Health Sciences/University of Western Ontario
• 2022–2023: CF Canada Clinical and Research Fellow, Toronto (Hospital for Sick Children, St. Michael’s Hospital), Toronto, Ontario, Canada.
• 2020–2022: Clinical Fellow, Paediatric Respiratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.
• 2016–2022: MD (Res), Royal Brompton Hospital/Imperial College, London, England, United Kingdom.
• 2011–2014: MRCPCH (Examination for the Royal College of Paediatrics and Child Health)
• 2007–2011: MBBS, Bart’s and the London School of Medicine, University of London, London, England, United Kingdom.

1. Co-Author. Eisha S, Morris AJ, Martin I, Yau YCW, Grasemann H, Waters V. Effect of L-arginine on cystic fibrosis Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0033624. doi: 10.1128/aac.00336-24. Epub 2024 Jul 18.
2. Co-Author. Akinkugbe O, Marchetto L, Martin I, Chia SH. Systematic Review and Meta-Analysis of the Incidence of Chronic Kidney Disease After Pediatric Critical Illness. Crit Care Explor. 2024 Jul 30;6(8):e1129. doi: 10.1097/CCE.0000000000001129.
3. Principle Author. Martin I, McDonald N, Wilson D, Ratjen F, Grasemann H. Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis. J Cyst Fibros. 2024 Jan;23(1):109-111. doi: 10.1016/j.jcf.2023.05.015. Epub 2023 Oct 21.
4. Principle Author. Martin I, Morales S, Alton EWFW, Davies JC. Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection. Antibiotics (Basel). 2023 Mar 16;12(3):593. doi: 10.3390/antibiotics12030593.
5. Co-Author. Perrem L, Martin I, Ratjen F. Outpatient management of pulmonary exacerbations in children with cystic fibrosis. Expert Rev Respir Med. 2023 Apr;17(4):295-304. doi: 10.1080/17476348.2023.2202852. Epub 2023 Apr 14.